mProX™ Human LY6G6D Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

LY6G6D is a tumor-associated antigen that has shown potential in various applications for the treatment of colorectal cancer. It is a member of the MHC class III lymphocyte antigen 6G (LY6G) family and is considered an endogenous immunotoxin. LY6G6D has been found to inhibit anti-tumor immunity in colorectal cancer with proficient mismatch repair. T-cell engagers (TcEs) have been developed to target LY6G6D on cancer cells and CD3 on T cells, improving the treatment of metastatic solid tumors that are resistant to immune checkpoint inhibitors. LY6G6D has been identified as a selectively expressed colorectal cancer antigen that can be used to target a therapeutic T-cell response. It has demonstrated potent tumor cell killing and T cell activation in vitro and has shown tumor regressions in pre-clinical mouse models. LY6G6D can also modulate colorectal cancer through p38α MAPK and DNA methylation, and its expression is related to histological subtypes and epigenomic changes. Additionally, a novel anti-LY6G6D/CD3 T-cell-dependent bispecific antibody has been developed for the treatment of colorectal cancer, which exhibits potent antitumor activity in vitro and in vivo. Overall, LY6G6D shows promise as a target for immunotherapy in colorectal cancer.